AR011607A1 - Polipeptido aislado que codifica un supresor tumoral ts10q23.3, anticuerpo monoclonal , celula de hibridoma, antisuero policlonal, acido nucleico yoligonucleotido aislados. metodo para diagnosticar cancer, alterar el fenotipo de una celula tumoral, determinar el estadio de un cancer, pronosticar - Google Patents

Polipeptido aislado que codifica un supresor tumoral ts10q23.3, anticuerpo monoclonal , celula de hibridoma, antisuero policlonal, acido nucleico yoligonucleotido aislados. metodo para diagnosticar cancer, alterar el fenotipo de una celula tumoral, determinar el estadio de un cancer, pronosticar

Info

Publication number
AR011607A1
AR011607A1 ARP980100442A ARP980100442A AR011607A1 AR 011607 A1 AR011607 A1 AR 011607A1 AR P980100442 A ARP980100442 A AR P980100442A AR P980100442 A ARP980100442 A AR P980100442A AR 011607 A1 AR011607 A1 AR 011607A1
Authority
AR
Argentina
Prior art keywords
cancer
tumor suppressor
gene
tumor
isolated
Prior art date
Application number
ARP980100442A
Other languages
English (en)
Spanish (es)
Original Assignee
Univ Texas
Myriad Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25152739&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR011607(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Texas, Myriad Genetics Inc filed Critical Univ Texas
Publication of AR011607A1 publication Critical patent/AR011607A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
ARP980100442A 1997-01-30 1998-01-30 Polipeptido aislado que codifica un supresor tumoral ts10q23.3, anticuerpo monoclonal , celula de hibridoma, antisuero policlonal, acido nucleico yoligonucleotido aislados. metodo para diagnosticar cancer, alterar el fenotipo de una celula tumoral, determinar el estadio de un cancer, pronosticar AR011607A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/791,115 US6262242B1 (en) 1997-01-30 1997-01-30 Tumor suppressor designated TS10Q23.3

Publications (1)

Publication Number Publication Date
AR011607A1 true AR011607A1 (es) 2000-08-30

Family

ID=25152739

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980100442A AR011607A1 (es) 1997-01-30 1998-01-30 Polipeptido aislado que codifica un supresor tumoral ts10q23.3, anticuerpo monoclonal , celula de hibridoma, antisuero policlonal, acido nucleico yoligonucleotido aislados. metodo para diagnosticar cancer, alterar el fenotipo de una celula tumoral, determinar el estadio de un cancer, pronosticar

Country Status (14)

Country Link
US (1) US6262242B1 (enExample)
EP (2) EP2366712A3 (enExample)
JP (5) JP2001511002A (enExample)
AR (1) AR011607A1 (enExample)
AT (1) ATE499444T1 (enExample)
AU (1) AU745296B2 (enExample)
CA (1) CA2278849C (enExample)
DE (1) DE69842141D1 (enExample)
DK (1) DK0972024T4 (enExample)
ES (1) ES2361044T5 (enExample)
IL (1) IL131168A0 (enExample)
PT (1) PT972024E (enExample)
WO (1) WO1998033907A1 (enExample)
ZA (1) ZA98756B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6287854B1 (en) 1996-10-22 2001-09-11 Imperial Cancer Research Technology Limited Diagnosis of susceptibility to cancer and treatment thereof
US6482795B1 (en) 1997-01-30 2002-11-19 Myriad Genetics, Inc. Tumor suppressor designated TS10q23.3
WO1998034624A1 (en) * 1997-02-07 1998-08-13 The Trustees Of Columbia University In The City Of New York Use of the p-ten suppressor gene in diagnosis and treatment of cancer
US6225120B1 (en) 1997-05-15 2001-05-01 The General Hospital Corporation Therapeutic and diagnostic tools for impaired glucose tolerance conditions
US6861256B2 (en) * 1997-05-15 2005-03-01 The General Hospital Corporation Therapeutic and diagnostic tools for impaired glucose tolerance conditions
AU8479498A (en) * 1997-07-08 1999-02-08 Cold Spring Harbor Laboratory Dual specificity phosphatase and methods of use
CA2301199C (en) * 1997-08-26 2013-02-05 Myriad Genetics, Inc. A tumor suppressor designated ts10q23.3
AU2002226028A1 (en) 2000-11-14 2002-05-27 Board Of Regents, Unversity Of Texas Systems Mutant human factor ix with an increased resistance to inhibition by heparin
AU2002359697A1 (en) * 2001-12-20 2003-07-09 Tularik Inc. Identification of an amplified gene and target for drug intervention
WO2005044091A2 (en) * 2003-11-05 2005-05-19 Board Of Regents, The University Of Texas System Diagnostic and therapeutic methods and compositions involving pten and breast cancer
BRPI0711011A2 (pt) 2006-05-18 2011-08-23 Molecular Profiling Inst Inc método para a determinação da intervenção médica para um estado de doença, método para a identificação de uma terapia de droga com capacidade de interação com um alvo molecular e sistema para a determinação da intervenção médica individualizada para um estado de doença
US8768629B2 (en) * 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
EP3216874A1 (en) 2008-09-05 2017-09-13 TOMA Biosciences, Inc. Methods for stratifying and annotating cancer drug treatment options
EP3181705A1 (en) * 2008-11-12 2017-06-21 Caris Life Sciences Switzerland Holdings GmbH Methods and systems of using exosomes for determining phenotypes
CN103237901B (zh) 2010-03-01 2016-08-03 卡里斯生命科学瑞士控股有限责任公司 用于治疗诊断的生物标志物
CA2795776A1 (en) 2010-04-06 2011-10-13 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Circulating biomarkers for disease
KR20130113447A (ko) 2010-09-24 2013-10-15 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 고정된 프라이머들을 이용하여 표적 dna의 직접적인 캡쳐, 증폭 및 서열화
US9617601B2 (en) 2011-12-30 2017-04-11 Abbott Molecular Inc. Materials and methods for diagnosis, prognosis and assessment of therapeutic/prophylactic treatment of prostate cancer

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4196265A (en) 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
US4883750A (en) 1984-12-13 1989-11-28 Applied Biosystems, Inc. Detection of specific sequences in nucleic acids
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
EP0273085A1 (en) 1986-12-29 1988-07-06 IntraCel Corporation A method for internalizing nucleic acids into eukaryotic cells
AU622104B2 (en) 1987-03-11 1992-04-02 Sangtec Molecular Diagnostics Ab Method of assaying of nucleic acids, a reagent combination and kit therefore
FR2616841A1 (fr) 1987-06-17 1988-12-23 Rauner Hans Perfectionnements au systeme de bloquage en position ouverte a levier de serrage pivotant, pour fiches et paumelles de portes et de fenetres
IL86724A (en) 1987-06-19 1995-01-24 Siska Diagnostics Inc Methods and kits for amplification and testing of nucleic acid sequences
CA1323293C (en) 1987-12-11 1993-10-19 Keith C. Backman Assay using template-dependent nucleic acid probe reorganization
EP0359789B1 (en) 1988-01-21 1993-08-04 Genentech, Inc. Amplification and detection of nucleic acid sequences
CA1340807C (en) 1988-02-24 1999-11-02 Lawrence T. Malek Nucleic acid amplification process
US4932207A (en) 1988-12-28 1990-06-12 Sundstrand Corporation Segmented seal plate for a turbine engine
US5279721A (en) 1993-04-22 1994-01-18 Peter Schmid Apparatus and method for an automated electrophoresis system
KR19990067011A (ko) 1995-10-23 1999-08-16 임페리얼 캔서 리서치 테크놀로지 리미티드 암에 대한 감수성 진단 및 그 치료방법
CA2301199C (en) * 1997-08-26 2013-02-05 Myriad Genetics, Inc. A tumor suppressor designated ts10q23.3
US8312249B1 (en) 2008-10-10 2012-11-13 Apple Inc. Dynamic trampoline and structured code generation in a signed code environment
FR2957821B1 (fr) 2010-03-24 2014-08-29 Inst Francais Du Petrole Nouvelle zone de regeneration du catalyseur divisee en secteurs pour unites catalytiques regeneratives

Also Published As

Publication number Publication date
PT972024E (pt) 2011-05-05
CA2278849C (en) 2016-04-19
ZA98756B (en) 1998-08-25
JP4768783B2 (ja) 2011-09-07
US6262242B1 (en) 2001-07-17
WO1998033907A1 (en) 1998-08-06
JP2009039107A (ja) 2009-02-26
EP0972024A1 (en) 2000-01-19
JP2013128485A (ja) 2013-07-04
EP2366712A3 (en) 2012-11-14
IL131168A0 (en) 2001-01-28
CA2278849A1 (en) 1998-08-06
AU6018998A (en) 1998-08-25
JP2001511002A (ja) 2001-08-07
DK0972024T3 (da) 2011-04-26
AU745296B2 (en) 2002-03-21
EP2366712A2 (en) 2011-09-21
DK0972024T4 (da) 2014-07-07
DE69842141D1 (de) 2011-04-07
ATE499444T1 (de) 2011-03-15
EP0972024B1 (en) 2011-02-23
JP5202583B2 (ja) 2013-06-05
JP2014155493A (ja) 2014-08-28
ES2361044T3 (es) 2011-06-13
JP2010259438A (ja) 2010-11-18
ES2361044T5 (es) 2014-10-01
EP0972024B2 (en) 2014-06-25

Similar Documents

Publication Publication Date Title
AR011607A1 (es) Polipeptido aislado que codifica un supresor tumoral ts10q23.3, anticuerpo monoclonal , celula de hibridoma, antisuero policlonal, acido nucleico yoligonucleotido aislados. metodo para diagnosticar cancer, alterar el fenotipo de una celula tumoral, determinar el estadio de un cancer, pronosticar
Park et al. Merkel cell polyomavirus activates LSD1-mediated blockade of non-canonical BAF to regulate transformation and tumorigenesis
Sethi et al. A global analysis of the complex landscape of isoforms and regulatory networks of p63 in human cells and tissues
Petrović et al. The prognostic significance of the circulating neuroendocrine markers chromogranin A, pro-gastrin-releasing peptide, and neuron-specific enolase in patients with small-cell lung cancer
Abascal et al. Subfunctionalization via adaptive evolution influenced by genomic context: the case of histone chaperones ASF1a and ASF1b
Eguchi et al. Intracellular MMP3 promotes HSP gene expression in collaboration with chromobox proteins
Lux et al. Circular RNAs in cancer
EA199700447A1 (ru) Последовательность днк и кодируемый ею специфический для молочной железы белок карциномы молочной железы
AR006250A1 (es) Compuestos y metodos para la inmunoterapia e inmunodiagnostico del cancer prostatico
ATE329030T1 (de) Nukleinsäure, welche einen von lektin abstammenden faktor zur präservierung von progenitorzellen kodiert
Bergman et al. Isolation, Characterization, and Primary Structure of a Calcium-binding 63-kDa Bone Protein (∗)
Schneider et al. Evidence that vitronectin is a potent migration-enhancing factor for cancer cells chaperoned by fibrinogen: a novel view of the metastasis of cancer cells to low-fibrinogen lymphatics and body cavities
Parrish et al. Size heterogeneity, phosphorylation and transmembrane organisation of desmosomal glycoproteins 2 and 3 (desmocollins) in MDCK cells
Lee et al. The effects of DLEU1 gene expression in Burkitt lymphoma (BL): potential mechanism of chemoimmunotherapy resistance in BL
Kolovskaya et al. DNA-aptamer/protein interaction as a cause of apoptosis and arrest of proliferation in Ehrlich ascites adenocarcinoma cells
Yoon et al. NOTUM is involved in the progression of colorectal cancer
Frost et al. The dimerization state of the mammalian high mobility group protein AT-hook 2 (HMGA2)
Myers et al. Type XIX collagen purified from human umbilical cord is characterized by multiple sharp kinks delineating collagenous subdomains and by intermolecular aggregates via globular, disulfide-linked, and heparin-binding amino termini
Wang et al. Transcriptional analysis of the expression, prognostic value and immune infiltration activities of the COMMD protein family in hepatocellular carcinoma
Vegliante et al. NR1H3 (LXRα) is associated with pro‐inflammatory macrophages, predicts survival and suggests potential therapeutic rationales in diffuse large b‐cell lymphoma
Teshima et al. Comparison of properties of stem cells isolated from adipose tissue and lipomas in dogs
Boukouris et al. A reversible metabolic stress-sensitive regulation of CRMP2A orchestrates EMT/stemness and increases metastatic potential in cancer
UY24389A1 (es) Composición farmacéutica para el tratamiento de carcinoma de epitelio plano
Deng et al. iTRAQ-based quantitative proteomic analysis of esophageal squamous cell carcinoma
ATE298003T1 (de) Ein tumorsuppressor namens ts10q23.3

Legal Events

Date Code Title Description
FA Abandonment or withdrawal